Becker Muscular Dystrophy
Condition Description
Becker muscular dystrophy (BMD) is an inherited condition that causes progressive weakness and wasting of the skeletal and cardiac (heart) muscles. It primarily affects males. In some cases, heart involvement (cardiomyopathy) is the first sign. BMD is caused by a genetic change in the DMD gene and is inherited in an X-linked recessive manner. BMD is very similar to Duchenne muscular dystrophy, except that in BMD, symptoms begin later and progress at a slower rate. People with BMD may survive into their 40s or beyond.
Active Trials
-
TRIAL TITLE: A Study of EDG-5506 in Adult and Adolescent Males With Becker Muscular Dystrophy
DESCRIPTION: The CANYON study is a double-blind, placebo-controlled, Phase 2 study of EDG-5506 to assess the safety, biomarkers, and pharmacokinetics (PK) of EDG-5506 in adults and adolescents with Becker muscular dystrophy (BMD). EDG-5506 is an investigational product intended to protect and improve function of dystrophic muscle fibers.
SPONSOR: Edgewise Therapeutics, Inc.
INDICATION: Becker Muscular Dystrophy
STUDY PROTOCOL: EDG-5506-001
PHASE: 2
STATUS: Active
RECRUITING PATIENTS: Yes
-
TRIAL TITLE: A Study to Asses the Long-term Effects of EDG-5506 on Safety, Biomarkers, and Functional Measures in Adults and Adolescents With Becker Muscular Dystrophy
DESCRIPTION: The MESA study is a open-label, treatment extension study to evaluate the safety, tolerability, and durability of effect in long-term dosing of EDG-5506. EDG-5506-203 MESA will provide continued access to EDG-5506 treatment to participants with Becker muscular dystrophy who were previously enrolled in EDG-5506-002 ARCH, completed EDG-5506-201 CANYON and GRAND CANYON, or completed EDG-5506-202 DUNE.
SPONSOR: Edgewise Therapeutics, Inc.
INDICATION: Becker Muscular Dystrophy
STUDY PROTOCOL: EDG-5506-001
PHASE: 2
STATUS: Active
RECRUITING PATIENTS: Yes
-
TRIAL TITLE: CureDuchenne Link®: A Resource to Support Research Studies in Duchenne and Becker Muscular Dystrophy (DMD/BMD).
DESCRIPTION: CureDuchenne link is a data hub comprised of integrated biospecimens, clinical data, and self- and/or caregiver-reported information from participants. Anyone over 4 weeks old who has been diagnosed with DMD or BMD or who is a carrier of DMD or BMD can join. Parents or legal guardians can sign up their child(ren).
SPONSOR: CureDuchenne
INDICATION: Duchenne Muscular Dystrophy/ Becker Muscular Dystrophy
STUDY PROTOCOL: CD-2021-01
PHASE: NA
STATUS: Active
RECRUITING PATIENTS: Yes
Upcoming Trials
Past Trials
-
TRIAL TITLE: A Study of EDG-5506 in Adult Males With Becker Muscular Dystrophy (ARCH)
DESCRIPTION: The ARCH study is an open-label, single-center, Phase 1b study of EDG-5506 to assess the safety and pharmacokinetics (PK) of EDG-5506 in adults with Becker muscular dystrophy (BMD). EDG-5506 is an investigational product intended to protect and improve function of dystrophic muscle fibers.
SPONSOR: Edgewise Therapeutics, Inc.
INDICATION: Becker Muscular Dystrophy
STUDY PROTOCOL: EDG-5506-002
PHASE: 1b
STATUS: Closing
RECRUITING PATIENTS: No